Robert Keith Warner net worth and biography

Robert Warner Biography and Net Worth

Director of RxSight

Mr. Warner has served as a member of our Board since August 2021, at which time he was nominated to serve as a member of the Compensation Committee and the chair of the Governance Committee. Mr. Warner served as President and General Manager of Alcon Vision Care Franchise Alcon Laboratories (NYSE:ALC) from August 2015 until February 2018. Prior to that, Mr. Warner served as President, U.S. and Canada, for Alcon from January 2012 to July 2015 and as President, Canada and Latin America, for Alcon from November 2010 to January 2012. From January 2005 to October 2010, Mr. Warner served in increasing positions of responsibility for Alcon. Mr. Warner was a member of the Alcon Executive Leadership Team for over 10 years and led the Alcon transition from Nestle (OTCMKTS:NSRGY) to Novartis (NYSE:NVS) majority ownership. Mr. Warner currently serves on the board of directors of two private medical device companies, i Lumen Scientific and EyeYon Medical (serving as Chairman for the latter), and is also a board member of Inari Medical (serving as a member of the Audit Committee) (NASDAQ:NARI) and a nonprofit organization, GRACE, the Grapevine Relief and Community Exchange. Mr. Warner holds a B.S. in Chemistry from Pace University and an MBA from Rutgers University.

What is Robert Keith Warner's net worth?: The estimated net worth of Robert Keith Warner is at least $390,480.64 as of January 8th, 2024. Warner owns 27,733 shares of RxSight stock worth more than $390,481 as of April 14th. This net worth approximation does not reflect any other investments that Warner may own. Learn More about Robert Keith Warner's net worth.
How do I contact Robert Keith Warner?: The corporate mailing address for Warner and other RxSight executives is , , . RxSight can also be reached via phone at 949-521-7830 and via email at ir@rxsight.com. Learn More on Robert Keith Warner's contact information.
Has Robert Keith Warner been buying or selling shares of RxSight?: Robert Keith Warner has not been actively trading shares of RxSight within the last three months. Most recently, Robert Keith Warner sold 23,750 shares of the business's stock in a transaction on Monday, January 8th. The shares were sold at an average price of $42.69, for a transaction totalling $1,013,887.50. Following the completion of the sale, the director now directly owns 27,733 shares of the company's stock, valued at $1,183,921.77. Learn More on Robert Keith Warner's trading history.
Who are RxSight's active insiders?: RxSight's insider roster includes Julie Andrews (Director), Juliet Bakker (Director), Jesse Corley (Director), Tamara Fountain (Director), Ilya Goldshleger (Insider), Ilya Goldshleger (Insider), M Kurtz (CEO), William Link (Director), Shweta Maniar (Director), Shelley Thunen (CFO), Robert Warner (Director), and Eric Weinberg (Insider). Learn More on RxSight's active insiders.
Are insiders buying or selling shares of RxSight?: In the last year, RxSight insiders bought shares 2 times. They purchased a total of 12,554 shares worth more than $549,098.81. In the last year, insiders at the sold shares 28 times. They sold a total of 160,951 shares worth more than $8,269,376.44. The most recent insider tranaction occured on March, 12th when Director Tamara Fountain sold 7,000 shares worth more than $179,970.00. Insiders at RxSight own 9.4% of the company. Learn More about insider trades at RxSight.
Information on this page was last updated on 3/12/2025.

Robert Keith Warner Insider Trading History at RxSight

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/8/2024	Sell	23,750	$42.69	$1,013,887.50	27,733
12/11/2023	Sell	5,498	$35.08	$192,869.84	23,750
12/8/2023	Sell	14,502	$35.01	$507,715.02	29,248

Robert Keith Warner Buying and Selling Activity at RxSight

RxSight Company Overview

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Today's Range

Now: $14.08

$13.50

$14.56

50 Day Range

MA: $25.63

$14.08

$34.26

2 Week Range

Now: $14.08

$13.50

$66.54

Volume

1,102,327 shs

Average Volume

605,044 shs

Market Capitalization

$570.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26